Originally published on PharmacyTimes.com.
Michael Zeglinski, RPh, Senior Vice President of Specialty Pharmacy OptumRx, Chief Executive Officer at Avella and BriovaRx Specialty Pharmacies recently penned this article in Specialty Pharmacy Times about ways the health system can be optimized for patient care.
Avella team members were recently featured in an ASHP article discussing the CareSpeak text message program.
A pilot project at Avella Specialty Pharmacy suggests that text message reminders can help patients with chronic and complex conditions stay on track with their therapy and potentially have better clinical outcomes.
Thursday, August 23rd 2018 - Avella EVP of Clinical and Quality Assurance, Eric Sredzinski, was named a finalist for the Phoenix Business Journal Health Care Heroes Awards in the Non-Physician category.
As an executive vice president at Avella Specialty Pharmacy, Eric Sredzinski is responsible for the development and oversight of all clinical programs and services provided by Avella.
Avella EVP of Clinical and Quality Assurance, Eric Sredzinski, was recently quoted in the following Specialty Pharmacy Continuum article.
“While commercial and Medicare Part D patients are seeing rising cost-sharing requirements and greater demand for assistance, the increasing contributions from drug companies over the past five years seem to be plateauing,” Daniel Klein, the president and CEO of the Patient Access Network (PAN) Foundation, said during the Asembia 2018 Specialty Pharmacy Summit.
The following article was written by Avella's EVP of Clinical & Quality Assurance, Eric Sredzinski, and published in Specialty Pharmacy Times.
Oncology is already among the top therapeutic classes in specialty pharmacy.1 Experts say that drugs to fight cancer will continue to dominate the next wave of FDA approvals and enter the market at a rapid pace. Yet specifically how these medications are delivered to patients is also expected to evolve over time. This is especially true as manufacturers look to partner with specialty pharmacies that possess highly specific expertise in supporting patients with cancer and their complex treatment regimens.
PHOENIX, AZ–Avella Specialty Pharmacy has just published new data showing that automated patient engagement, in combination with patient monitoring and trigger-based pharmacist interventions, have a significant impact on patient adherence and persistence.
The specialty pharmacy uses AdhereTech smart pill bottles for multiple specialty medications from various manufacturers, with consistent improvements in adherence, duration, refills, and the patient experience.
Phoenix, AZ – Avella Specialty Pharmacy and AdhereTech are proud to share the results that their successful partnership continues to have for patients. Avella currently uses the AdhereTech program for five specialty medications, in programs with four different pharmaceutical manufacturers. Averaged across all patients and programs from 2015 through today, AdhereTech has improved duration on therapy by 26%, fill rates by 9%, and dose-level adherence by 15%. On average, the AdhereTech program generates 1 to 2 additional fills of specialty medications, per patient per year.
The specialty pharmacy will give patients access to this important new FDA-approved combination therapy for patients with advanced BRAF melanoma.
Phoenix, AZ -- Avella has announced that it will distribute BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib), a combination therapy recently FDA approved for patients for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.
At Asembia Specialty Pharmacy Summit 2018, Kelly Mathews, PharmD, CSP, the director of clinical services and residency program director at Avella Specialty Pharmacy, discusses the paradigm shift in treating patients with inflammatory bowel disease with Christopher T. Owens, PharmD, MPH, the associate vice president, Kasiska Division of Health Sciences, Idaho State University.